Gart Michael S, Gutowski Karol A
Chicago, Ill. From the Department of Surgery, Division of Plastic and Reconstructive Surgery, Northwestern Memorial Hospital; and Division of Plastic Surgery, University of Illinois.
Plast Reconstr Surg. 2015 Nov;136(5 Suppl):62S-71S. doi: 10.1097/PRS.0000000000001773.
The introduction of neuromodulators for aesthetic facial improvements greatly expanded the limits of nonsurgical facial rejuvenation. Although many current uses are considered "off-label," the widespread acceptance and favorable safety profile of properly used botulinum toxins have made them one of the most common aesthetic treatments available.
A literature review of current facial aesthetic uses of various botulinum toxin preparations was done, and general concepts were identified.
Currently, Food and Drug Administration-approved botulinum toxin preparations onabotulinumtoxinA (Botox), abobotulinumtoxinA (Dysport), and incobotulinumtoxinA (Xeomin) have similar off-label indications and clinical uses.
Although not considered interchangeable, administration and clinical outcomes are not much different between the 3 commonly used botulinum products. The impact of botulinum products currently in development has yet to be determined.
用于面部美容改善的神经调节剂的引入极大地扩展了非手术面部年轻化的界限。尽管目前许多用途被认为是“非标签”的，但正确使用肉毒杆菌毒素的广泛接受度和良好的安全性使其成为最常见的美容治疗方法之一。
对各种肉毒杆菌毒素制剂目前在面部美学方面的应用进行了文献综述，并确定了一般概念。
目前，美国食品药品监督管理局批准的肉毒杆菌毒素制剂，即A型肉毒毒素（保妥适）、A型肉毒杆菌毒素（丽舒妥）和A型肉毒毒素（吉适），具有相似的非标签适应症和临床用途。
尽管这三种肉毒杆菌毒素产品不被认为可以互换使用，但它们在给药方式和临床效果上并无太大差异。目前正在研发的肉毒杆菌毒素产品的影响尚未确定。
